Liposomes-Based Anti-Biofilm Drug Delivery – Comprehensive Study Notes

Citation & Publication Facts

• Authors: Zinb Makhlouf, Amaal Abdulraqeb Ali, Mohammad Hussein Al-Sayah

• Article: “Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation”

• Journal: Antibiotics 2023; Vol $12$; No. $5$; Article $875$ (published on page $875$ of Volume $12$, Issue $5$), indicating it's a peer-reviewed open-access journal focused on antimicrobial research.

• DOI: $10.3390/antibiotics12050875$ (Digital Object Identifier, ensuring persistent access and citation of the article).

• Timeline:

  • Manuscript Received: $15$ Apr $2023$

  • Underwent Revision and Resubmitted: $2$ May $2023$

  • Accepted for Publication: $4$ May $2023$

  • Officially Published Online: $8$ May $2023$

• License: Creative Commons Attribution (CC-BY $4.0$), which is an open-access license granting broad permissions for unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are appropriately credited. This facilitates wider dissemination and utilization of the research.

Abstract – Core Take-Aways

• Antibiotic Resistance and Biofilms: All current antibiotic classes face increasing resistance, presenting a significant global health crisis. Bacterial biofilms are a primary driver of this resistance due to their unique structural defenses (e.g., the EPS matrix) and physiological alterations within embedded bacteria, which collectively render them highly tolerant (often $10$ to $1,000$ -fold more resistant) to conventional antimicrobial therapies.

• Liposomal Delivery Systems: Liposomes are versatile nanocarriers increasingly recognized for their potential in drug delivery, particularly for anti-biofilm agents. They consist of lipid bilayers capable of encapsulating both hydrophilic drugs (in their aqueous core) and hydrophobic drugs (within the lipid bilayer). Various types exist, including charged, neutral, stimuli-responsive, deformable, targeted, and stealth liposomes, which can be engineered to protect drugs from degradation, enhance their stability, improve pharmacokinetics, and promote their targeted accumulation at infection sites, thereby maximizing therapeutic efficacy while minimizing systemic toxicity.

• Broad Efficacy: Significant efficacy of liposomal formulations has been consistently reported against biofilms formed by a wide range of clinically important bacteria. This includes prevalent Gram-negative pathogens such as Pseudomonas aeruginosa (a major cause of chronic lung infections in cystic fibrosis patients) and Escherichia coli (common in urinary tract infections), as well as stubborn Gram-positive pathogens like Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA], a leading cause of hospital-acquired infections) and Staphylococcus epidermidis (frequently associated with medical device-related infections).

• Future Research Directions: The review emphasizes several critical areas for future study to translate liposomal anti-biofilm strategies into clinical practice:

  • Investigating the specific influence of Gram-stain characteristics (e.g., cell wall structure and outer membrane in Gram-negatives) on liposome-biofilm interactions and uptake mechanisms.

  • Extending research to understudied but clinically significant pathogens (e.g., Mycobacterium tuberculosis, responsible for tuberculosis; Neisseria gonorrhoeae, a common cause of sexually transmitted infections; and various anaerobic bacteria).

  • Optimizing liposomal design (e.g., surface charge, lipid composition, size) to overcome various in vivo delivery barriers (e.g., host immune clearance, deep tissue penetration) and achieve more potent and targeted anti-biofilm effects in complex biological environments.

Introduction – Why Biofilms Matter

• Ubiquitous Formation: Biofilms are intricate, highly organized communities of microorganisms that irreversibly attach to surfaces and are encased in a self-produced extracellular polymeric substance (EPS) matrix. They can adhere to virtually any surface, including inert materials like medical devices (e.g., catheters, prosthetic joints, dental implants), industrial surfaces (e.g., water pipes, drains, heat exchangers), and living tissues (e.g., lungs in cystic fibrosis, chronic wounds on the skin, oral cavity [dental plaque], urinary tract). Their pervasive nature makes them a significant challenge in healthcare and industry.

• Biofilm Matrix Composition and Tolerance: The biofilm matrix is a complex, viscoelastic hydrogel primarily composed of a diverse array of macromolecules: polysaccharides (e.g., exopolysaccharides providing structural integrity), proteins (e.g., enzymes, adhesion proteins), and extracellular nucleic acids (eDNA, contributing to structural stability and gene transfer). This dense, protective matrix establishes a formidable diffusion barrier that significantly impedes the penetration of antibiotics, disinfectants, and host immune cells. This physical hindrance, coupled with altered metabolic states of embedded bacteria, leads to an estimated $1,000$-fold increase in antibiotic tolerance and resistance compared to their free-floating (planktonic) counterparts.

• Clinical Significance: Alarmingly, an estimated 65–80 ext{%} of all microbial infections and a staggering 80 ext{%} of chronic human infections are now associated with biofilm formation. These include, but are not limited to, persistent wound infections (e.g., diabetic foot ulcers, pressure sores), medical device-related infections (e.g., central line-associated bloodstream infections, prosthetic joint infections, endocarditis), chronic respiratory infections (e.g., in cystic fibrosis patients), chronic otitis media, periodontitis, and recurrent urinary tract infections. Biofilm-associated infections are notoriously difficult to treat and often necessitate surgical intervention or removal of infected devices.

• Urgent Threat of Resistance: The global health community forecasts that by $2050$, resistant infections could become the leading cause of death worldwide, potentially surpassing cancer and leading to immense human suffering and economic burden. This grim projection underscores the critical and immediate need for innovative and effective therapeutic strategies to combat antimicrobial resistance, particularly those targeting biofilms.

• Unmet Need for Anti-Biofilm Drugs: Despite the profound and escalating impact of biofilms on public health, there is currently no specific anti-biofilm drug that has received standalone approval for clinical use. This highlights a significant therapeutic void and emphasizes the urgent necessity for innovative drug delivery systems, such as liposomes, capable of overcoming the inherent resistance mechanisms and penetration barriers of biofilms to deliver antimicrobial agents effectively.

Biofilm Biology in Brief

• Formation Steps: Biofilm development is a highly dynamic, multi-step process, influenced by environmental factors and bacterial gene expression:

  1. Reversible Attachment: This initial stage involves weak, non-specific adhesion of planktonic cells to a surface. Forces such as van der Waals interactions, electrostatic forces, and hydrophobic interactions mediate this attachment. At this point, cells can still detach and return to a planktonic lifestyle.

  2. Irreversible Adhesion: Bacteria firmly attach to the surface, often utilizing specific cell-surface adhesion proteins (adhesins), pili, fimbriae, or flagella. This irreversible binding represents a commitment to biofilm formation and is typically followed by a shift in gene expression profiles.

  3. Micro-colony Growth and EPS Production: Following irreversible adhesion, attached cells begin to proliferate through cell division, forming small clusters known as micro-colonies. Concurrently, they initiate the synthesis and secretion of the extracellular polymeric substance (EPS) matrix, which starts to encase the growing cell clusters.

  4. EPS Maturation and Architecture: The biofilm undergoes extensive maturation, characterized by robust and complex production of the EPS matrix. This matrix creates a heterogeneous, three-dimensional structure with specialized microenvironments. Within this architecture, nutrient channels and water conduits develop, facilitating the diffusion of nutrients to deeper layers of the biofilm and the removal of metabolic waste products, thus supporting the survival and growth of the entire community.

  5. Dispersion: Under specific environmental cues, such as nutrient limitation, changes in pH, oxygen availability, or host immune responses, some cells can detach from the mature biofilm. These detached cells, often reverting to a planktonic state, can then colonize new sites, initiating new cycles of biofilm formation and contributing to the dissemination of infection throughout the host or environment.

• Defensive Traits: Biofilms employ multiple sophisticated strategies to evade both host immune defenses and the effects of antimicrobial agents:

  • Quorum Sensing (QS): A highly coordinated cell-to-cell communication system that allows bacteria to monitor their population density through the release and detection of secreted signaling molecules called autoinducers. QS regulates collective behaviors critical for biofilm survival, including EPS production, the expression of virulence factors (e.g., toxins, enzymes), and contributing to communal antibiotic resistance.

  • Dormancy/Persister Cells: A subpopulation of cells within the biofilm that enter a non-dividing, metabolically inactive or low-activity state. These persister cells are phenotypically tolerant to high concentrations of antibiotics, even those targeting actively metabolizing cells. They are not genetically resistant but can survive antibiotic treatment and subsequently resuscitate, leading to recurrent infections once the antibiotic pressure is removed.

  • Diffusion Barrier of EPS: The dense EPS matrix physically limits and slows the penetration of antibiotics into the deeper layers of the biofilm, reducing the effective concentration of the drug at the bacterial cell surface.

  • Altered Metabolism and Gene Expression: Bacteria within biofilms often exhibit a slower growth rate and altered metabolic profiles compared to planktonic cells. This physiological change can render them less susceptible to antibiotics that primarily target rapidly dividing or metabolically active cells.

  • Efflux Pumps: Biofilm-embedded bacteria can upregulate expression of efflux pumps, which are membrane proteins that actively pump out various antimicrobial compounds from the cell, reducing their intracellular concentration.